Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia
Shots:
- Alopexx to receive up front- development & commercialization milestones along with royalties on sales. Beijing Shenogen Pharma get an exclusive license to develop & commercialize DI-Leu16-IL2 in China and other parts of Asia
- The therapy is evaluated in P-I study assessing DI-LEU16-IL2 in 18 patients with r/r B-cell CD20+ lymphoma who received 2 or more cycles of therapy had tumor regression or stabilization including 3 complete and 2 partial responses
- DI-LEU16-IL2 is a novel immune-cytokine targeting CD20- developed by Merck KGaA and licensed to Provenance in 2009. Later in 2011- Provenance rights to develop & commercialize the therapy to Alopexx
Click here to read full press release/ article | Ref: PRNewswire | Image: Alopexx
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com